,NAD+-MBOAT2,SLC25A21,SOX6

Xu Zeng1, Kexue Zhang2, Ming Liang2

  • 1Department of Neurosurgery, The Seventh Medical Center of PLA General Hospital, Beijing, China.

概括

尼古丁胺胺二核酸 (NAD+) 治疗改善了临床评分,并减少了实验性自身免疫脑炎 (EAE) 小鼠的炎症. 虽然NAD+在EAE中显示出潜力,但它并没有显著改变脊髓细胞中差异表达的基因.